Amendments to the Claims:

This listing of the claims will replace all prior versions and listings of the claims in the application:

1-28. (Canceled)

29. (Currently Amended) A pharmaceutical emulsion composition for parenteral delivery, said composition consisting essentially of, in combination:

(a) a hydrophilic phase;

(b) from about 2 to 40 percent volume per volume of a pharmacologically acceptable lipoid as a hydrophobic phase dispersed as particles in said hydrophilic phase, wherein said lipoid is soybean oil, and wherein said particles are from 5 to 1000 nanometers in diameter;

(c) from about 0.01 to 2 percent weight per volume of fenretinide;

(d) from about 0.01 to 10 percent volume per volume of ethanol;

(e) from about 0.01 to 10 percent weight per volume of a surfactant to stabilize said emulsion composition, wherein said surfactant is selected from egg phospholipids; and

(f) from about 1 to 10 percent weight per volume of glycerin;

said emulsion composition having a pH of about 5 to 10.

30. (Previously Presented) The composition of claim 29 wherein fenretinide is present at about 0.1 to 0.5 percent weight per volume.

31. (Currently Amended) The composition of claim 29 wherein ~~the solvent is~~ ethanol is present at about 0.01 to 5.0 percent volume per volume.

32. (Canceled)

33. (Currently Amended) The composition of claim 29 wherein the ~~surfactant is~~ egg phospholipid is present at about 2 percent weight per volume.

34. (Previously Presented) The composition of claim 29 wherein the glycerin is present in an amount of about 1 to 3 percent weight per volume.

35. (Canceled)

36. (Previously Presented) The composition of claim 29 wherein said particles are from 50 to 400 nanometers in diameter.

37. (Currently Amended) The composition of claim 29 wherein:

fenretinide is present at about 0.1 to 0.5 percent weight per volume;

~~the solvent is~~ ethanol is present at about 0.01 to 5.0 percent volume per volume;

~~said surfactant is~~ egg phospholipid is present at about 2 percent weight per volume;

~~said isotonic agent is~~ wherein glycerin ~~and~~ is present in an amount of about 1 to 3 percent weight per volume; and

said particles are from 50 to 400 nanometers in diameter.

38. (Previously Presented) A method of treating a hyperproliferative disorder in a subject in need thereof, comprising parenterally administering to said subject a composition according to claim 29 in an amount effective to treat said hyperproliferative disorder.

39. (Previously Presented) The method of claim 38, further comprising the step of diluting said composition in an aqueous pharmaceutically acceptable carrier prior to said administering step.

40. (Previously Presented) The method of claim 38, wherein said administering step is an intravenous administration step.

41. (Previously Presented) The method of claim 38, wherein said subject is a human subject.